Gary S Gronseth1, Richard Barohn1, Pushpa Narayanaswami1. 1. From the Department of Neurology (G.S.G., R.B.), University of Kansas Medical Center, Kansas City; and Department of Neurology (P.N.), Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: To review updated evidence regarding the effectiveness of thymectomy for treating patients with myasthenia gravis (MG). METHODS: The practice advisory panel performed a systematic review and developed practice recommendations using methods developed by the American Academy of Neurology. RESULTS: One Class I study of patients younger than 65 years with nonthymomatous acetylcholine receptor antibody-positive (AChR ab+) generalized MG demonstrated better clinical outcomes in patients treated with oral prednisone and undergoing thymectomy compared with patients treated with prednisone alone, including an increased probability of attaining minimal manifestation status (no symptoms or functional limitations). CONCLUSION: For patients with nonthymomatous AChR ab+ generalized MG, treatment with thymectomy plus prednisone is probably more effective than treatment with prednisone alone for increasing the chance of attaining minimal manifestation status (risk difference at 36 months, 20%; 95% confidence interval, 1.6%-37%; moderate confidence in the evidence). RECOMMENDATIONS: Clinicians should discuss thymectomy treatment with patients with AChR ab+ generalized MG (Level B). Clinicians should counsel patients with AChR ab+ generalized MG considering minimally invasive thymectomy techniques that it is uncertain whether the benefit attained by extended transsternal thymectomy will also be attained by minimally invasive approaches (Level B).
OBJECTIVE: To review updated evidence regarding the effectiveness of thymectomy for treating patients with myasthenia gravis (MG). METHODS: The practice advisory panel performed a systematic review and developed practice recommendations using methods developed by the American Academy of Neurology. RESULTS: One Class I study of patients younger than 65 years with nonthymomatous acetylcholine receptor antibody-positive (AChR ab+) generalized MG demonstrated better clinical outcomes in patients treated with oral prednisone and undergoing thymectomy compared with patients treated with prednisone alone, including an increased probability of attaining minimal manifestation status (no symptoms or functional limitations). CONCLUSION: For patients with nonthymomatous AChR ab+ generalized MG, treatment with thymectomy plus prednisone is probably more effective than treatment with prednisone alone for increasing the chance of attaining minimal manifestation status (risk difference at 36 months, 20%; 95% confidence interval, 1.6%-37%; moderate confidence in the evidence). RECOMMENDATIONS: Clinicians should discuss thymectomy treatment with patients with AChR ab+ generalized MG (Level B). Clinicians should counsel patients with AChR ab+ generalized MG considering minimally invasive thymectomy techniques that it is uncertain whether the benefit attained by extended transsternal thymectomy will also be attained by minimally invasive approaches (Level B).
Authors: Rocio Castillo-Larios; Daniel Hernandez-Rojas; Aaron C Spaulding; Alejandra Yu Lee-Mateus; Priyanka Pulipaka; Dorin T Colibaseanu; Mathew Thomas; Sebastian Fernandez-Bussy; Ian A Makey Journal: Gland Surg Date: 2022-06
Authors: Jakob Rath; Manuela Taborsky; Bernhard Moser; Gudrun Zulehner; Rosa Weng; Martin Krenn; Hakan Cetin; José Ramon Matilla; Leonhard Müllauer; Fritz Zimprich Journal: Eur J Neurol Date: 2022-04-30 Impact factor: 6.288
Authors: Pushpa Narayanaswami; Donald B Sanders; Gil Wolfe; Michael Benatar; Gabriel Cea; Amelia Evoli; Nils Erik Gilhus; Isabel Illa; Nancy L Kuntz; Janice Massey; Arthur Melms; Hiroyuki Murai; Michael Nicolle; Jacqueline Palace; David Richman; Jan Verschuuren Journal: Neurology Date: 2020-11-03 Impact factor: 9.910